1. Home
  2. RENX vs RNAZ Comparison

RENX vs RNAZ Comparison

Compare RENX & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenX Enterprises Corp. Common Stock

RENX

RenX Enterprises Corp. Common Stock

N/A

Current Price

$0.10

Market Cap

7.3M

Sector

N/A

ML Signal

N/A

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

N/A

Current Price

$8.60

Market Cap

8.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RENX
RNAZ
Founded
2021
2016
Country
United States
United States
Employees
6
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
8.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RENX
RNAZ
Price
$0.10
$8.60
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$280.00
AVG Volume (30 Days)
8.4M
8.7K
Earning Date
03-31-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.50
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.22
52 Week High
$0.35
$20.99

Technical Indicators

Market Signals
Indicator
RENX
RNAZ
Relative Strength Index (RSI) 36.63 39.44
Support Level N/A $8.47
Resistance Level $0.17 $11.62
Average True Range (ATR) 0.02 0.56
MACD -0.00 -0.12
Stochastic Oscillator 4.37 13.49

Price Performance

Historical Comparison
RENX
RNAZ

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Share on Social Networks: